Monoclonal antibodies in the treatment of human B-cell malignancies

Leukemia and Lymphoma

Volumn 31, Issue 3-4, 1998, Pages 237-249

  Link, Brian K ^a   Weiner, George J ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

B cell lymphoma; Immunotoxin; Monoclonal antibody; Radioimmunotherapy

Indexed keywords

CHIMERIC ANTIBODY; IMMUNOTOXIN; MONOCLONAL ANTIBODY;

ANTIBODY STRUCTURE; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; DRUG EFFICACY; HUMAN; IMMUNOGENICITY; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REMISSION; REVIEW; SIDE EFFECT;

EID: 0032421923     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199809059217     Document Type: Review

References (89)

1. Baumler, E. (1984) Paul Ehrlich: Scientist for Life.
2. Pressman, D. and Korngold L. (1953) The in vivo localization of anti-Waaner-osteogenic sarcoma antibodies. Cancer, 6, 619-623.
3. Kohler, G. and Milstein C. (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256, 495-7.
4. [41 Stein, R., Belisle E., Hansen H.J. and Goldenberg D.M. (1993) Epitope Specificity of the Anti-(B-Cell Lymphoma) Monoclonal Antibody, LL2. Cancer Immunol Immunother, 37, 293-298.
5. Nadler, L.M., Stashenko P., Hardy R. and Schlossman S.F. (1980) A monoclonal antibody defining a lymphoma-associated antigen in man. Journal of Immunology, 125, 570-7.
6. Epstein, A.L., Marder R.J., Winter J.N., Stathopoulos E., Chen F.-M., Parker J.W. and Taylor C.R. (1987) Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Research, 47, 830-840.
7. Lucas, K.G., Pollok K.E. and Emanuel D.J. (1997) POST-TRANSPLANT EBV INDUCED LYMPIIOPROLIFERATIVE DISORDERS [Review]. Leukemia & Lymphoma, 25, 1-8.
8. Sullivan, K.M., Storb R., Buckner C.D., Fefer A., Fisher L., Weiden P.L., Witherspoon R.P., Appelbaum F.R., Banaji M., Hansen J. and et al. (1989) Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. New England Journal of Medicine, 320, 828-34.
9. Slavin, S. and Strober S. (1978) Spontaneous murine B-cell leukemia. Nature, 272, 624.
10. Maloney, D.G., Kaminski M.S., Burowski D., Haimovich J. and Levy R. (1986) Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38C13: characterization and use as probes for the biology of the tumor in vivo and in vitro. Hybridoma, 4, 191-209.
11. Meeker, T.C., Lowder J., Maloney D.G., Miller R.A., Thielemans K., Warnke R. and Levy R. (1985) A clinical trial of anti-idiotype therapy for B cell malignancy. Blood, 65, 1349-63.
12. Lowder, J.N., Meeker T.C., Campbell M., Garcia C.F., Gralow J., Miller R.A., Wamke R. and Levy R. (1987) Studies on B lymphoid tumors treated with monoclonal anti-idiotype antibodies: correlation with clinical responses. Blood, 69, 199-210.
13. Levy, R. and Miller R.A. (1990) Therapy of lymphoma directed at idiotypes. Journal of the National Cancer Institute. Monographs, 61-8.
14. Nadler, L.M., Stashenko P., Hardy R., Kaplan W.D., Button L.N., Kufe D.W., Antman K.H. and Schlossman S.F. (1980) Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Research, 40, 3147-54.
15. Weiner, G.J. and Kaminski M.S. (1989) Idiotype variants emerging after anti-idiotype monoclonal antibody therapy of a murine B cell lymphoma. Journal of Immunology, 142, 343-51.
16. Jefferis, R., Lund J. and Pound J. (1990) Molecular definition of interaction sites on human IgG for Fc receptors (huFc gamma R). Molecular Immunology, 27, 1237-40.
17. Slavin-Chiorini, D.C., Horan Hand P.H., Kashmiri S.V., Calvo B., Zaremba S. and Schlom J. (1993) Biologic properties of a CH2 domain-deleted recombinant immunoglobulin. International Journal of Cancer, 53, 97-103.
18. LoBuglio, A.F., Wheeler R.H., Trang J., Haynes A., Rogers K., Harvey E.B., Sun L., Ghrayeb J. and Khazaeli M.B. (1989) Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proceedings of the National Academy of Sciences of the United States of America, 86, 4220-4.
19. Davis, T., Levy R., White C.A., Maloney D.G., Link B.K., Velasquez C., Vams C., Gardner C. and Grillo-Lopez A.J. (1996) Retreatments with RITUXAN (Rituximab, IDEC-C2b8) have significant efficacy, do not cause HAMA, and are a viable minimally toxic alternative in relapsed or refractory non-Hodgkin's lymphoma (NHL). Blood, 90, 509a.
20. Riechmann, L., Clark M., Waldmann H. and Winter G. (1988) Resharping human antibodies for therapy. Nature, 332, 323.
21. Queen, C., Schneider W.P., Selick H.E., Payne P.W., Landolfi N.F., Duncan J.F., Avdalovic N.M., Levitt M., Junghans R.P. and Waldmann T.A. (1989) A humanized antibody that binds to the interleukin 2 receptor. P roc. Natl.Acad. Sci. USA, 86, 10029-10033.
22. Fujimori, K., Covell D.G., Fletcher J.E. and Weinstein J.N. (1990) A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. Journal of Nuclear Medicine, 31, 1191-8.
23. Chignola, R., Pasti M., Candiani C., Franceschi A., Anselmi C., Tridente G. and Colombatti M. (1995) Escape mechanisms of human leukemic cells to long-term immunotoxin treatment in an in vitro experimental model. Int J Cancer, 61, 535-541.
24. Hirsch, R., Gress R.E., Pluznik D.H., Eckhaus M. and Blue-stone J.A. (1989) Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells. J Immunol, 142, 737-43.
25. Vervoordeldonk, S.F., Merle P.A., van Leeuwen E.F., von dem Borne A.E. and Slaper-Cortenbach I.C. (1994) Preclinical studies with radiolabeled monoclonal antibodies for treatment of patients with B-cell malignancies. Cancer, 73, 1006-11.
26. Meeker, T., Lowder J., Cleary M.L., Stewart S., Warnke R., Sklar J. and Levy R. (1985) Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype anti-bodies. N Engl J Med. 312, 1658-65.
27. Baluyut, A.R., Pollok K.E. and Bondada S. (1993) Molecular events in B lymphocyte activation: Consequences of signals transduced through MHC class II molecules. Cellular Immunology, 147, 353-366.
28. Barren, T.B., Shu G.L., Draves K.E., Pezzutto A. and Clark E.A. (1990) Signaling through CD19, Fc receptors or transforming growth factor-beta: each inhibits the activation of resting human B cells differently. European Journal of Immunology, 20, 1053-9.
29. Beckwith, M., Urba W.J., Ferris D.K., Freter C.E., Kuhns D.B., Moratz C.M. and Longo D.L. (1991) Anti-IgM-mediated growth inhibition of a human B lymphoma cell line is independent of phosphatidylinositol turnover and protein kinase C activation and involves tyrosie phosphorylation. Journal of Immunology, 147, 2411-2418.
30. Beiske, K., Clark E.A., Holte H., Ledbetter J.A., Smeland E.B. and Godai T. (1988) Triggering of neoplastic B cells via surface IgM and the cell surface antigens CD20 and CDw40. Responses differ from normal blood B cells and are restricted to certain morphologic subsets. International Journal of Cancer, 42, 521-8.
31. Bishop, G.A., Warren W.D. and Berton M.T. (1995) Signaling via major histocompatibility complex class II molecules and antigen receptors enhances the B cell response to gp39/CD40 ligand. Eur J Immunol, 25, 1230-1238.
32. Clark, E.A. and Shu G. (1987) Activation of human B cell proliferation through surface Bp35 (CD20) polypeptides or immunoglobulin receptors. Journal of Immunology, 138, 720-5.
33. Doody, G.M., Dempsey P.W. and Fearon D.T. (1996) Activation of B lymphocytes: Integrating signals from CD19, CD22 and Fc gamma RIIb1. Curr Opin Immunol, 8, 378-382.
34. Ledbetter, J.A., Shu G., Gallagher M. and Clark E.A. (1987) Augmentation of normal and malignant B cell proliferation by monoclonal antibody to the B cell-specific antigen BP50 (CDW40). Journal of Immunology, 138, 788-94.
35. Tedder, T.F., Forsgren A., Boyd A.W., Nadler L.M. and Schlossman S.F. (1986) Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes. European Journal of Immunology, 16, 881-7.
36. Brown, S.L., Miller R.A. and Levy R. (1989) Antiidiotype antibody therapy of B-cell lymphoma. Semin Oncol, 16, 199-210.
37. Miller, R.A., Maloney D.G., Warnke R. and Levy R. (1982) Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. New England Journal of Medicine, 306, 517-22.
38. Vlasveld, L.T., Hekman A., Vythdreese F.A., Melief C.J.M., Sein J.J., Voordouw A.C., Dellemijn T.A.M. and Rankin E.M. (1995) Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19. Cancer Immunol Immunother, 40, 37-47.
39. Press, O.W., Appelbaum F., Ledbetter J.A., Martin P.J., Zarling J., Kidd P. and Thomas E.D. (1987) Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood, 69, 584-91.
40. Scheinberg, D.A., Straus D.J., Yeh S.D., Divgi C., Garin-Chesa P., Graham M., Pentlow K., Coit D., Oettgen H.F. and Old L.J. (1990) A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expression. Journal of Clinical Oncology, 8, 792-803.
41. Canon, P.C., Schwartz M.A., Co M.S., Queen C., Finn R.D., Graham M.C., Divgi C.R., Larson S.M. and Scheinberg D.A. (1994) Murine and Humanized Constructs of Monoclonal Antibody M195 (Anti-Cd33) for the Therapy of Acute Myelogenous Leukemia. Cancer, 73, 1049-1056.
42. Haga, Y., Sivinski C.L., Woo D. and Tempero M.A. (1994) Dose-related comparison of antibody-dependent cellular cytotoxicity with chimeric and native murine monoclonal antibody 17-1A. Improved cytolysis of pancreatic cancer cells with chimeric 17-1A. International Journal of Pancreatology, 15, 43-50.
43. Meredith, R.F., Khazaeli M.B., Grizzle W.E., Orr R.A., Plott G., Urist M.M., Liu T., Russell CD., Wheeler R.H., Schlom J. and et al. (1993) Direct localization comparison of murine and chimeric B72.3 antibodies in patients with colon cancer. Human Antibodies & Hybridomas, 4, 190-7.
44. Weiden, P.L., Breitz H.B., Seiler C.A., Bjorn M.J., Ratliff B.A., Mallett R., Beaumier P.L., Appelbaum J.W., Fritzberg A.R. and Salk D. (1993) Rhenium-186-labeled chimeric antibody NR-LU-13: pharmacokinetics, biodistribution and immunogenicity relative to murine analog NR-LU-10. Journal of Nuclear Medicine, 34, 2111-9.
45. Dyer, M.J. (1993) Chimeric antibodies for the treatment of hematologic malignancy. (72 Refs). Cancer Treatment & Research, 68, 161-80.
46. Shitara, K., Kuwana Y., Nakamura K., Tokutake Y., Ohta S., Miyaji H., Hasegawa M. and Hanai N. (1993) A mouse/human chimeric anti-(ganglioside GD3) antibody with enhanced antitumor activities. Cancer Immunology, Immunotherapy, 36, 373-80.
47. Dyer, M.J., Hale G., Marcus R. and Waldman R. (1990) Remission induction in patients with lymphoid malignancies using unconjugated Campath-1 monoclonal antibodies. Leukemia and Lymphoma, 2, 179-193.
48. Dyer, M.J., Hale G., Hayhoe F.G. and Waldmann H. (1989) Effects Of Campath-1 Antibodies In Vivo In Patients With Lymphoid Malignancies: Influence Of Antibody Isotype. Blood, 73, 1431-9.
49. Xia, M.Q., Hale G. and Waldmann H. (1993) Efficient complement mediated-lysis of cells containing the Campath-1H (CDw52) antigen. Molecular Immunology, 30.
50. Osterborg, A., Dyer M.J., Bunjes D., Pangalis G.A., Bastion Y., Catovsky D. and Mellstedt H. (1997) Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAM-PATH-1H Treatment in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 15, 1567-74.
51. Osterborg, A., Passas A.S., Anagnostopoulos A., Dyer M.J., Catovsky D. and Mellstedt H. (1996) Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. British Journal of Haematohgy, 93, 151-3.
52. Tang, S.C., Hewitt K. and Berinstein N.L. (1995) Objective clinical responses in patients with recurrent low grade lymphoma treated with CAMPATH-1H monoclonal antibody (Meeting abstract). Proc Anna Meet Am Soc Clin Oncol, 14, A1255.
53. de Nully Brown, P., Hansen M.M. and Nissen N.I. (1997) [Campath-1H-a monoclonal antibody for treatment of non-Hodgkin's and chronic lymphatic leukemia]. Ugeskrift for Laeger, 159, 4389-93.
54. Bowen, A.L., Zomas A., Emmett E., Matutes E., Dyer M.J. and Catovsky D. (1997) Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. British Journal of Haematology, 96, 617-9.
55. Reff, M.E., Camer K., Chambers K.S., Chinn P.C., Leonard J.E., Raab R., Newman R.A., Hanna N. and Anderson D.R. (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood, 83, 435-45.
56. Maloney, D.G., Liles T.M., Czerwinski D.K., Waldichuk C., Rosenberg J., Grillo-Lopez A. and Levy R. (1994) Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood, 84, 2457-66.
57. Maloney, D.G., Grillolopez A.J., White C.A., Bodkin D., Schilder R.J., Neidhart J.A., Janakiraman N., Foon K.A., Liles T.M., Dallaire B.K., Wey K., Royston I., Davis T. and Levy R. (1997) Idec-C2b8 (Rituximab) Anti-Cd20 Monoclonal Antibody Therapy Patients With Relapsed Low-Grade Non-Hodgkins Lymphoma. Blood, 90, 2188-2195.
58. Maloney, D.G., Grillo-Lopez A.J., Bodkin D.J., White C.A., Liles T.M., Royston I., Varns C., Rosenberg J. and Levy R. (1997) Idec-C2b8 - Results Of a Phase I Multiple-Dose Trial In Patients With Relapsed Non-Hodgkins Lymphoma. Journal of Clinical Oncology, 15, 3266-3274.
59. McLaughlin, P., Grillo-Lopez A.J., Czuczman M., Link B.K., Levy R., Dillman R.O., Ho A., Bennett J.M., Heyman M.R., Schilder R.J., Cabanillas F., Rogers J. and Dallaire B.K. (1996) Preliminary Report on a Phase III Pivotal Trial of the Anti-CD20 Antibody IDEC-C2B8 in Patients with Relapsed Low Grade or Follicular Lymphoma. Proceedings American Society of Clinical Oncology, 15, 417.
60. Demidem, A., Lam T., Alas S., Hariharan K., Hanna N. and Bonavida B. (1997) Chimeric Anti-Cd20 (Idec-C2b8) Monoclonal Antibody Sensitizes Cell Lymphoma Cell Line to Cell Killing By Cytotoxic Drugs. Cancer Biotherapy & Radiopharmaceuticals, 12, 177-186.
61. Czuczman, M., Grillo-Lopez A.J., Saleh M., Gordon L., Jonas C. and Vams C. (1995) Phase II clinical trial of IDEC-C2B8/CHOP combination therapy in low-grade lymphoma: preliminary results (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol, 14, A1261.
62. Herpst, J.M., Klein J.L., Leichner P.K., Quadri S.M. and Vriesendorp H.M. (1995) Survival of patients with resistant Hodgkin's disease after polyclonal yttrium 90-labeled antiferritin treatment. Journal of Clinical Oncology, 13, 2394-400.
63. Corcoran, M.C., Eary J., Bernstein I. and Press O.W. (1997) Radioimmunotherapy strategies for non-Hodgkin's lymphomas. Annals of Oncology, 8, 133-8.
64. Wilder, R.B., DeNardo G.L. and DeNardo S.J. (1996) Radioimmunotherapy: recent results and future directions. Journal of Clinical Oncology, 14, 1383-400.
65. Appelbaum, F.R. (1991) Radiolabeled Monoclonal Antibodies in the Treatment of Non-Hodgkin's Lymphoma. Hematology - Oncology Clinics of North America, 5, 1013-1025.
66. Knox, S.J., Levy R., Miller R.A., Uhland W., Schiele J., Ruehl W, Finston R., Day L.P. and Goris M.L. (1990) Determinants of the antitumor effect of radiolabeled monoclonal antibodies. Cancer Res, 50, 4935-40.
67. Mattes, M.J., Griffiths G.L., Diril H., Goldenberg D.M., Ong G.L. and Shin L.B. (1994) Processing of Antibody-Radioisotope Conjugates After Binding to the Surface of Tumor Cells. Cancer. 73, 787-793.
68. Buchsbaum, D.J., Wahl R.L., Glenn S.D., Normolle D.P. and Kaminski M.S. (1992) Improved Delivery of Radiolabeled Anti-B1 Monoclonal Antibody to Raji Lymphoma Xenografts by Predosing with Unlabeled Anti-B1 Monoclonal Antibody. Cancer Res, 52, 637-642.
69. Press, O.W., Eary J.F., Appelbaum F.R., Martin P.J., Badger C.C., Nelp W.B., Glenn S., Butchko G., Fisher D., Porter B. and et al. (1993) Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support [see comments]. New England Journal of Medicine. 329, 1219-24.
70. Press, O.W., Eary J.F., Appelbaum F.R., Martin P.J., Nelp W.B., Glenn S., Fisher D.R., Porter B., Matthews D.C., Gooley T. and et al. (1995) Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet, 346, 336-40.
71. Kaminski, M.S., Fig L.M., Zasadny K.R., Koral K.F., DelRosario R.B., Francis I.R., Hanson C.A., Normolle D.P., Mudgett E., Liu C.P., Moon S., Scott P., Miller R.A. and Wahl R.L. (1992) Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. Journal of Clinical Oncology, 10, 1696-1711.
72. Kaminski, M.S., Zasadny K.R., Francis I.R., Fenner M.C., Ross C.W., Milik A.W., Estes J., Tuck M., Regan D., Fisher S., Glenn S.D. and Wahl R.L. (1996) Iodine - 131-anti-B1 radioimmunotherapy for B-cell lymphoma. Journal of Clinical Oncology, 17, 1974-1981.
73. Lewis, J.P., Denardo G.L. and Denardo S.J. (1995) Radioimmunotherapy of lymphoma: a UC Davis experience. Hybridoma, 14, 115-20.
74. Goldenberg, D.M., Horowitz J.A., Sharkey R.M., Hall T.C., Murthy S., Goldenberg H., Lee R.E., Stein R., Siegel J.A., Izon D.O. and et al. (1991) Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody [see comments]. Journal of Clinical Oncology, 9, 548-64.
75. Knox, S.J., Goris M.L., Trisler K., Negrin R., Davis T., Liles T.-M., Grillo-Lopez A., Chinn P., Vams C., Shou-Cheng N., Fowler S., Nimisha D., Becker M., Marquez C. and Levy R. (1996) Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clinical Cancer Research, 2, 457-170.
76. White, C.A., Halpern S.E., Parker B.A., Miller R.A., Hupf H.B., Shawler D.L., Collins H.A. and Royston I. (1996) Radioimmunotherapy of relapsed B-cell lymphoma with Yttrium anti-idiotype monoclonal antibodies. Blood, 87, 3640-3649.
77. Frankel, A.E., Fitzgerald D., Siegall C. and Press O.W. (1996) Advances in immunotoxin biology and therapy: A summary of the Fourth International Symposium on Immunotoxins. Cancer Res, 56, 926-932.
78. Ghetie, V. and Vitetta E. (1994) Immunotoxins in the therapy of cancer: From bench to clinic. Pharmacol Ther, 63, 209-234.
79. Grossbard, M.L. and Nadler L.M. (1994) Immunotoxin Therapy of Lymphoid Neoplasms. Semin Hematol, 31, 88-97.
80. Vitetta, E.S., Stone M., Amlot P., Fay J., May R., Till M., Newman J., Clark P., Collins R., Cunningham D., Ghetie V., Uhr J.W. and Thorpe P.E. (1991) Phase-I Immunotoxin Trial in Patients with B-Cell Lymphoma. Cancer Research, 51, 4052-4058.
81. Amlot, P.J., Stone M.J., Cunningham S.D., Fay J., Collins N.R., May R., McCarthy M., Richardson J., Ghetie V., Ramilo O., Thorpe P.E., Uhr J.W. and Vitetta E.S. (1993) A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood, 82, 2624-2633.
82. Sausville, E.A., Headlee D., Stetler-Stevenson M., Jaffe E.S., Solomon D., Figg W.D., Herdt J., Kopp W.C., Rager H., Steinberg S.M. and et al. (1995) Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMFT-dgA in patients with B-cell lymphoma: a phase I study. Blood, 85, 3457-65.
83. Stone, M.J., Sausville E.A., Fay J.W., Headlee D., Collins R.H., Figg W.D., Stetler-Stevenson M., Jain V., Jaffe E.S., Solomon D., Lush R.M., Senderowicz A., Ghetie V., Schlindler J., Uhr J.W. and Vitetta E.S. (1996) A phase I study of bolus versus continuous infusion of the anti-CD 19 immunotoxin, Ig-HD37-dgA in patients with B-cell lymphoma. Blood, 88, 118-1197.
84. Grossbard, M.L., Freedman A.S., Ritz J., Coral F., Goldmacher V.S., Eliseo L., Spector N., Dear K., Lambert J.M., Blattler W.A., Taylor J.A. and Nadler L.M. (1992) Serotherapy of B-Cell Neoplasms with Anti-B4-Blocked Ricin - A Phase-I Trial of Daily Bolus Infusion. Blood, 79, 576-585.
85. Grossbard, M.L., Lambert J.M., Goldmacher V.S., Spector N.L., Kinsella J., Eliseo L., Coral F., Taylor J.A., Blattler W.A., Epstein C.L. and Nadler L.M. (1993) Anti-B4-Blocked Ricin - A Phase-I Trial of 7-Day Continuous Infusion in Patients with B-Cell Neoplasms. J Clin Oncol, 11, 726-737.
86. Grossbard, M.L., Gribben J.G., Freedman A.S., Lambert J.M., Kinsella J., Rabinowe S.N., Eliseo L., Taylor J.A., Blattler W.A., Epstein C.L. and Nadler L.M. (1993) Adjuvant Immunotoxin Therapy with Anti-B4-Blocked Ricin After Autologous Bone Marrow Transplantation for Patients with B-Cell Non-Hodgkin's Lymphoma. Blood, 81, 2263-2271.
87. Grossbard, M.L., O'Day S., Gribben J.G., Kolesar C., Freedman A.S., Rabinowe S.N., Neuberg D., Esseltine D.L., Epstein C.L. and Nadler L.M. (1994) A Phase II study of anti-B4-blocked ricin (anti-B4-bR) therapy following autologous bone marrow transplantation (ABMT) for B-cell non-Hodgkin's lymphoma (B-NHL) (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol, 13, A951.
88. Vuist, W.M.J., Levy R. and Maloney D.G. (1994) lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein. Blood, 83, 899-906.
89. Vitetta, E.S., Tucker T.F., Racila E., Huang Y.W., Marches R., Lane N., Scheuermann R.H., Street N.B., Watanabe T. and Uhr J.W. (1997) Tumor dormancy and cell signaling. V. Regrowth of the BCL1 tumor after dormancy is established. Blood, 89, 4425-36.